COVID-19 testing 20% higher among patients with immune-mediated inflammatory disease

Patients with immune mediated inflammatory diseases are tested for COVID-19 at a 20% higher rate than the general population, according to data published in Arthritis Care & Research.However, despite this higher rate of testing, the risk for SARS-CoV-2 infection was not significantly higher among most patients with IMIDs compared with their non-IMID peers.“Despite multiple studies on the risk of COVID-19 infection and its complications in IMIDs, evidence from population-based studies is limited,” Lihi Eder, MD, PhD, of the University of Toronto Women’s College ResearchRead More

Share on facebook
Share on twitter
Share on linkedin